Oncolytics Biotech Gains FDA Agreement on Pivotal Study Design for Pelareorep in First-Line Metastatic Pancreatic Cancer

Company to launch only current registration trial with an immunotherapy in first-line pancreatic cancer in first half of 2026 Trial design allows flex...

November 20, 2025 | Thursday | News
Synthio Labs Raises $5M Seed Round to Transform Global Pharma Engagement with Clinical-Grade Voice AI

Synthio Labs, a clinical-grade voice AI company transforming how life sciences organisations engage clinicians and patients, announced that it has raised...

November 20, 2025 | Thursday | News
Thermo Fisher Opens Flagship United States Center in Philadelphia to Accelerate Cell & Gene Therapy Development

  New state-of-the-art facility in Philadelphia provides integrated lab and collaboration space along with tailored guidance to help move advanced th...

November 19, 2025 | Wednesday | News
Emerging EMEA: A Vital and Evolving Landscape for Biopharma Strategy, Offering a Blueprint for Agile Market Access and Global Patient Reach

  In these diverse and dynamic markets, adaptation is not a strategy; it is a prerequisite for thriving. Success requires a fundamental shift in mind...

November 19, 2025 | Wednesday | Opinion
HelixAI Launches Agentic OS Built for End-to-End R&D Automation, Backed by NVIDIA, AWS, and Sapio Sciences

New operating system enables scientists to move from copilot to autopilot, unifying diverse in silico, wet lab research and scientists to accelerate in...

November 19, 2025 | Wednesday | News
Thermo Fisher Scientific Enrolls First Patient in New PPD™ CorEvitas™ Myasthenia Gravis Registry

  Thermo Fisher Scientific Inc., the world leader in serving science, announced the enrollment of the first patient in the new PPD™ CorEvitas&t...

November 18, 2025 | Tuesday | News
Parse Biosciences’ GigaLab to Power 5 Million–TCR Mapping Effort With Third Rock Ventures

Third Rock Ventures and Parse Biosciences  announced a strategic collaboration to create an unprecedented atlas of 5 million T cell receptors (TCRs)...

November 17, 2025 | Monday | News
Repare Therapeutics Enters Definitive Agreement to Be Acquired by Xeno Therapeutics

Each shareholder is estimated to receive US$1.82 per share plus one CVR per common share - - Transaction expected to close in the first quarter of 20...

November 17, 2025 | Monday | News
Merck CEO Belén Garijo Confirms Confident Momentum Across Healthcare And Life Science

  Net sales increase organically by +5.2% to € 5.3 billion; foreign exchange effects of –4.9%, portfolio effects of +0.7% EBI...

November 14, 2025 | Friday | Company results
Kytopen and Excellos Partner to Explore Scalable Non-Viral Manufacturing for Next-Generation Cell Therapies

Collaboration will investigate how continuous flow cellular engineering and donor-to-dose manufacturing expertise may advance scalable, non-viral process...

November 13, 2025 | Thursday | News
Pixelgen Technologies and Carolina Molecular Partner to Bring 3D Protein Interactomics to U.S. Researchers

Carolina Molecular Inc., a leading molecular testing services laboratory, and Pixelgen Technologies AB announced  a partnership to expand access to ...

November 13, 2025 | Thursday | News
Nurami Medical Advances Artifix® Toward First-in-Human Trials With Successful Phase 1 Completion

Nurami Medical, a company developing next-generation regenerative solutions for soft tissue repair, has announced successful completion of Phase 1 of...

November 11, 2025 | Tuesday | News
Novartis Opens Carlsbad Radioligand Therapy Manufacturing Site as Part of $23B US Investment Plan

Carlsbad location is company’s third US-based radioligand therapy (RLT) manufacturing site New site expands manufacturing footprint to meet fut...

November 11, 2025 | Tuesday | News
Merck Presents Phase 3 Data Showing Enlicitide Achieved Up to 60% LDL-C Reduction With Placebo-Like Safety

Enlicitide, designed to deliver antibody-like efficacy, has the potential to be the first approved oral PCSK9 inhibitor to lower LDL-C with a safety pr...

November 10, 2025 | Monday | Reports

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close